Adam Feuerstein @JNapodano Isn’t this $AMBS
Post# of 30028
Posted On: 12/06/2014 6:22:18 PM
Quote:
Adam Feuerstein
@JNapodano Isn’t this $AMBS deal a bit too much mission creep?
1:24pm - 17 Nov 14
Jason Napodano
@adamfeuerstein Not sure what you mean. Like taking on more than they can handle? Maybe GC can get advice from Martin? LOL
1:27pm - 17 Nov 14
Adam Feuerstein
@JNapodano Yes. How does skin substitutes fit into $AMBS?
1:27pm - 17 Nov 14
Jason Napodano
@adamfeuerstein Off the cusp, I think GC's strategy is to roll-up Orphan drugs, regardless of area of focus or indication. But fair point.
1:29pm - 17 Nov 14
I think the BOD would agree about becoming too "diffused" following the ESS acquisition if their plan was to actually hold onto lympro.
Quote:
Dr. Rubinfeld: Well the greatest challenge was actually not to overgrow and to become too diffused in what we are doing. In other words, I want to concentrate on the product line that we have now and the products in the pipeline to bring them to fruition. And toward that end, we also have strategies of spinouts and things of that sort. If we cannot really give the full advantage to some of these products to reach full potential, maybe then we would out- license them or spin them out into another company or division that could concentrate on them. We have this huge pipeline. We have a lot of products out there. We have probably the most patients in clinical trials in oncology in the United States so this is an enormous challenge. http://www.twst.com/interview/827
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼